c-LEcta enzymes allow efficient production of Human Milk Oligosaccharides

26.07.2016

Together with its industrial partner, the Danish biotech company Glycom, c-LEcta has developed new enzymes for the production of Human Milk Oligosaccharides (HMOs), that are well known to provide health benefits to infants.

The synthesis of the diverse and very complex structured HMOs is hardly accessible by chemical ways but facilitated by regioselective enzymes. Hence, c-LEcta with its key technologies in enzyme engineering and Glycom with its expertise in the development and commercialization of HMOs, established a highly efficient process for the enzymatic production of these specific oligosaccarides in a collaboration project. Applying c-LEcta’s proprietary patent-protected enzyme engineering platform, enzymes were developed to catalyze the transfer of carbohydrates between compounds for high yields in the complex target structures. Native enzyme activities were modified to improve the ratio of synthesis to hydrolysis by the factor of 10.000: Hydrolases were evolved to become transferases. These processes were recently presented at several international conferences, such as Gordon Research Conference on Biocatalysis, Biddeford, USA and the International Carbohydrate Symposium, New Orleans, USA.

Kontakt:
Weitere Infos unter http://www.c-lecta.com/

Diesen Artikel teilen

Gallerie

Ähnliche Themen

Simplyfined erhält Millionen-Förderung vom Bund

06.11.2024

1,7 Millionen Euro über zwei Jahre erhält das Gründerteam der TU Dortmund. Simplyfined arbeitet daran, Oleochemikalie...

Weiterlesen

Akribion Therapeutics GmbH sichert sich erste Seed-Finanzierungsrunde

05.11.2024

Akribion Therapeutics hat seine erste Seed-Finanzierungsrunde erfolgreich abgeschlossen und wird am 1. Dezember 2024 ...

Weiterlesen

BRAIN Biotech: Abspaltung von Akribion

01.11.2024

Akribion Therapeutics schließt einen exklusiven Lizenzvertrag mit der BRAIN Biotech AG für ihre CRISPR/Cas-Technologi...

Weiterlesen